Eli Lilly announces a new generation of KRAS inhibitor LY3537982
- Subversive discovery: Can lymph nodes promote the success of cancer immunotherapy?
- Major Discovery: Cancer cell PD-L1 does not inhibit T cell toxicity
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
Eli Lilly announces a new generation of KRAS inhibitor LY3537982
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Eli Lilly announces a new generation of KRAS inhibitor LY3537982, which is more than 10 times more active than AMG510.
RAS is the first oncogene identified in human tumors, but it has always been regarded as a “non-drugable” target. Epidemiology shows that KRAS mutations account for approximately 13% in NSCLC, approximately 3%-5% in colorectal cancer, and approximately 1%-2% in other solid tumors.
The fastest-growing KRAS-G12C irreversible inhibitor Sotorasib (AMG510) has submitted a marketing application at the end of last year and is expected to become the first KRAS targeted drug approved for marketing.
In 2019, Eli Lilly’s first KRAS G12C inhibitor, LY3499446, started clinical research, and the latter was terminated due to safety issues, and was lagging behind on the KRAS track.
Recently, Eli Lilly has made a strong comeback and announced the preclinical activity data of its new generation of KRAS G12C inhibitor LY3537982 at the AACR2021 annual meeting, which is expected to win back.
According to published data, LY3537982 is also a covalent KRAS-G12C inhibitor. It exhibits high target inhibitory activity in KRAS G12C mutant H23 and H358 lung cancer cell lines, with IC50 of 1.04 nM and 1.16 nM, respectively. In KRAS G12C mutant H358 cells, the inhibitory activity (IC50) of LY3537982 was at least 10 times higher than that of Sotorasib (AMG 510) and Adagrasib.
In the KRAS-G12C mutant (PDX) model, LY3537982 showed a significant tumor growth inhibitory effect at 3-30 mg/kg QD or BID, and even made tumors completely regressed.
In addition, LY3537982 showed a target occupancy rate of >90%, while the target occupancy rate of Sotorasib and Adagrasib was less than 70%.
However, whether the strong target occupancy rate of LY3537982 can promote the further improvement of clinical activity remains to be confirmed by clinical studies.
Currently, the KRAS-G12C inhibitors in the development stage include Yifang Biologics D-1553 (Phase I/II), Novartis’ JDQ443 (Phase I/II), Genetech’s RG6330 (Phase I), Johnson & Johnson’s ARS-3248 ( Phase I), BPI-421286 (IND) of Betta Pharmaceuticals, GH35 (IND) of Qinhao Pharmaceutical, and adagrasib (Phase III) of Mirati Therapeutics.
Eli Lilly’s strong return has added waves to the field of KRAS inhibitors. The former may not win the final victory, and the latter is expected to become the king. The field of KRAS inhibitors is full of thorns, opportunities and hopes, and patients will ultimately benefit from it.
Eli Lilly announces a new generation of KRAS inhibitor LY3537982
(source:internet, reference only)
Disclaimer of medicaltrend.org
